Kevin A. Camphausen, M.D.
Dr. Camphausen studies the interaction of novel drugs and radiotherapy in the treatment of Glioblastoma Multiforme in the laboratory using preclinical model systems and in the clinic running clinical trials.
As Chief, Dr. Camphausen guides the Branch’s clinical/translational program, which studies the role of new agents as both radiation sensitizers and radiation protectors. The integration of novel imaging, molecular profiling and state of the art treatment techniques keeps the Branch at the forefront of Radiation Oncology.
Open - RecruitingNCI Protocol ID NCI-16-C-0081Investigator Kevin A. Camphausen, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Theresa C Cooley Zgela 301-451-8905
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme:Prospective Determination of a Predictive Value for RecurrenceOpen - RecruitingNCI Protocol ID NCI-04-C-0200Investigator Kevin A. Camphausen, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Theresa Cooley-zgela 3014518905
Open - RecruitingNCI Protocol ID NCI-03-C-0241Investigator Kevin A. Camphausen, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Theresa Cooley- Zgela 3014518905
Open - RecruitingNCI Protocol ID NCI-02-C-0064Investigator Kevin A. Camphausen, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Theresa Cooley Zgela 3014518905
Open - RecruitingNCI Protocol ID NCI-00-C-0181Investigator Kevin A. Camphausen, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Theresa Cooley Zgela 3014518905
Open - RecruitingNCI Protocol ID NCI-00-C-0074Investigator Kevin A. Camphausen, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Theresa Cooley-Zgela 3014518905
It is predicted that there will be 1.2 million non-skin cancers diagnosed in North America in 2016; seventy-five percent of these (i.e., 900,000 cancer patients) will receive radiotherapy sometime during the course of their disease. Improving the efficacy of radiotherapy would significantly contribute to cancer treatment in general given its pervasiveness as an anti-neoplastic therapy. To date, advances in radiotherapy have primarily involved a variety of fractionation schemes, improved dose delivery, and improved localization. Intensity modulated radiation therapy (IMRT), which attempts to more precisely direct dose to the tumor and limit the dose to normal structures, may allow further schedule modification in the future. Because of the physical limitations of radiation dose delivery, further technical improvements are likely to provide only incremental benefits. For this reason, further increases in tumor control will require a greater understanding of the underlying tumor response to radiation. In addition to the recent advances in the technical aspects of radiation delivery, there has been considerable progress in the delineation of the molecules and processes that regulate cellular radiosensitivity and the characterization of the molecular responses to radiation.
These advances in fundamental radiobiology suggest that improvements in tumor control can be achieved through strategies that combine radiation and molecular targeting, which is the primary focus of my laboratory efforts. As an adjunct to these laboratory efforts, I have translated several of my laboratory findings into ROB clinical trials. We have recently completed a Phase II trial of the histone deacetylase inhibitor (HDACi), valproic acid (VA), in combination with Temodar and radiotherapy for patients with GBMs. This was a direct translation from studies in my laboratory showing that VA enhances the sensitivity of glioma cell lines to radiation both in vitro and in vivo (1).
Another area of translational research within my lab is the development of non-invasive surrogate biomarkers for tumor recurrence following irradiation. Current methods to evaluate patients after radiotherapy include a history and physical, laboratory studies and imaging. As none of these techniques is very sensitive to a small number of tumor cells, the development of surrogate biomarkers may allow earlier targeted adjuvant therapy only to those patients who may benefit. We are currently conducting a Phase II trial in patients with Glioblastoma multiforme (GBMs) comparing the patient's urinary VEGF and MMP-2 levels, as early biomarkers of disease progression following the completion of radiotherapy, to the clinical parameters that comprise the recursive partition analysis (RPA) of the Radiation Therapy Oncology Group (RTOG), which are currently used to stratify patients and predict progression free survival and overall survival.
Selected Recent Publications
Dr. Camphausen received his M.D. from Georgetown University in 1996. He completed his internship at Georgetown in 1997 and a residency in radiation oncology at the Joint Center for Radiation Therapy at Harvard Medical School in 2001. Dr. Camphausen spent two years working in the laboratory of Dr. Judah Folkman studying the interaction of angiogenesis inhibitors and radiotherapy. He joined the National Cancer Institute in July 2001 as a tenure-track investigator. He served as the deputy branch chief beginning in April 2004 and was appointed to branch chief of the Radiation Oncology Branch in 2008. Dr. Camphausen is board certified by the American Board of Radiology.
|Juliana De Sousa MSc.||Research Collaborator|
|Andrea Francesconi M.S.||Technical Laboratory Manager|
|Tatsuya Kawai Ph.D.||Postdoctoral Fellow (Visiting)|
|Tamalee Kramp||Research Biologist|
|Jennifer Lee Ph.D.||Postdoctoral Fellow (CRTA)|
|Jason E. Savage M.S.||Research Biologist|
|Mary Sproull B.S.||Research Biologist|
|Hongshik Yun Ph.D.||Postdoctoral Fellow (Visiting)|